Set and Setting in Psychedelic-Assisted Therapy: Why Context Modulates the Medicine

In psychedelic-assisted therapy, "set" (the patient's mindset) and "setting" (the physical and social environment) are not atmosphere. They are clinical variables that shape what a given dose does and whether the session is safe. This Canadian guide explains both, reviews the evidence, and describes how reputable clinics engineer them deliberately.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

• Set and setting is a clinical framework, not a vibe. Formalized by Leary, Litwin and Metzner (1963) and re-examined for modern clinical practice by Hartogsohn (2017, J Psychopharmacol, PMID 28443452), it is one of the better-evidenced organizing concepts in psychedelic medicine.
• "Set" = everything the patient brings internally. Mindset, expectations, intentions, personality, history, and acute state (sleep, hydration, mood) on dosing day.
• "Setting" = everything outside the patient's mind. Physical environment, music, clinical team, cultural elements, privacy. The clinic engineers this; the patient provides input.
• The same dose in different contexts produces different experiences and different safety profiles [Hartogsohn 2017; Carbonaro 2016; Preller and Vollenweider 2018].
• Two clinicians in the dosing room is a well-documented structural setting variable in MAPP1/MAPP2 MDMA-AT and COMP001 psilocybin protocols [Mitchell 2021; Mitchell 2023; Goodwin 2022].
• Music is a therapeutic variable, not background audio. Kaelen et al. (2018) showed music makes measurable contributions to subjective experience in psilocybin sessions.
• Set and setting is necessary, not sufficient. Strong set and setting supports safety and quality; it does not predict response and does not replace the substance, dose, screening, or integration.

If you are evaluating psychedelic-assisted therapy and want to understand how ATMA CENA constructs the therapeutic environment for your situation, book a free information call.

Where the framework comes from

"Set and setting" enters the modern psychedelic literature through Timothy Leary, George Litwin and Ralph Metzner's 1963 paper Reactions to psilocybin administered in a supportive environment (J Nerv Ment Dis, PMID 14087676). Leary and colleagues observed that the subjective effects of psilocybin varied widely across participants in ways that dose alone could not explain. Two clusters of variables seemed to predict the variation: the participant's psychological state ("set") and the environment of administration ("setting"). The framework was largely sidelined during the prohibition era, then re-examined for the modern clinical context by Ido Hartogsohn's 2017 article Set and Setting, Psychedelics and the Placebo Response (Journal of Psychopharmacology, PMID 28443452) and his 2017 review Constructing drug effects: A history of set and setting (Drug Science, Policy and Law). Hartogsohn's contribution was to argue, using the history of psychopharmacology and contemporary placebo research, that set and setting are not ancillary to the drug effect but constitutive of it: the pharmacology supplies a non-ordinary state; the set and setting shape what that state becomes. This framework is now embedded in the Mithoefer/Mitchell MDMA-AT manuals (MAPP1 and MAPP2), the COMP001 psilocybin protocol, and the contemporary ketamine-assisted psychotherapy literature [Dore 2019; Mathai 2023]. Reputable Canadian clinics treat set and setting as engineerable clinical variables.

What "set" actually means

"Set" is shorthand for everything the patient brings into the dosing room from inside their own mind. It is partly stable (personality, history, chronic mental state) and partly modifiable in the weeks before dosing. The modifiable parts are the explicit work product of the preparation phase of psychedelic-assisted therapy.

Components of "set" in current clinical practice:

• Psychological readiness. Has the patient understood what the substance does, what to expect, what is normal, and what would be a signal to communicate? This is built in preparation.
• Trust in the clinical team. Therapeutic alliance with the people who will be in the room is not optional decoration; it is the variable a patient leans on if difficult material arises.
• Clarity about intentions. What the patient hopes to explore, change, or sit with. Intentions are reference points, not outcome promises.
• Expectations management. What the patient has been told the medicine will and will not do. Over-promised expectations distort set; honest, evidence-grounded expectations stabilize it.
• Comfort with vulnerability. The willingness to allow material to surface. This is partly trait, partly trained in preparation, partly a function of trust in the team.
• Trauma history and triggers. Specific somatic, relational, and contextual triggers documented in preparation so the team can respond if they emerge during dosing.
• Acute state. Sleep, hydration, food, mood, and the events of the prior 48 hours all enter set. Patients who arrive sleep-deprived, hungry, or in acute conflict are working from a degraded baseline.

Set is not a personality test the patient passes or fails. It is the constellation a clinician maps and works with, and that the patient can deliberately shape in the days before dosing.

What "setting" actually means

"Setting" is everything outside the patient's mind: the physical, social, clinical, and cultural environment of the dosing session. The clinic engineers setting; the patient provides input on the variables that personalize meaningfully.

Components of "setting" in current clinical practice:

• Physical environment. Room aesthetics, lighting (typically dim, warm, indirect), temperature, comfort of the recliner or couch, blankets, pillows, art, and view. Hospital fluorescents and bare white walls are unfavourable settings; deliberately designed therapeutic rooms are favourable ones.
• Music. Curated audio is a setting variable in its own right. The choice between standardized and personalized playlists is a clinical and patient-preference decision (see section on music below).
• Social setting. Who is in the room. The two-clinician model is a structural setting choice. Whether a support person is present for parts of the session is a setting choice.
• Clinical setting. Medical safety equipment (blood pressure cuff, pulse oximeter, emergency medications) is present but, in most modern protocols, functionally available without being visually prominent.
• Cultural elements. A meaningful object, a brief grounding practice, a chosen reading, a moment of silence at the start. Cultural elements are patient-led, never imposed, and clinically reviewed.
• Privacy and confidentiality. No interruptions, no inadvertent observers, phones silenced, door signage in place, charting completed before the session begins.

A well-engineered setting is not lavish; it is intentional. Every variable has been considered and either chosen or deliberately neutralized.

Why set and setting matter: the evidence

The core claim in modern psychedelic medicine is that dose-response is real but set and setting substantially modulate it [Hartogsohn 2017; Preller and Vollenweider 2018, PMID 28025814]. Three lines of evidence support this.

1. Subjective experience varies far more than dose alone predicts. Within a fixed dose, the spread of subjective intensity, emotional tone, and content is substantial. The variables that explain that spread are predominantly psychological state and contextual variables, not pharmacokinetic ones [Carbonaro 2016, PMID 27578767; Preller and Vollenweider 2018].

2. Adverse-experience clustering is contextual. Carbonaro et al. (2016) surveyed 1,993 individuals describing their most psychologically difficult psilocybin experience (PMID 27578767). Clustering of distress and prolonged adverse effect was associated with poor preparation, unsupportive setting, and inadequate support rather than with dose. Importantly, 84% of respondents endorsed long-term benefit from the experience despite its difficulty. Adverse events in the controlled-trial literature similarly concentrate where preparation and setting were suboptimal.

3. Same substance, different context, different outcome. Comparative work across clinical and recreational contexts, between MAPS-style MDMA delivery and less structured MDMA use, between supervised psilocybin and unsupervised use, between ketamine as infusion only and ketamine as psychotherapy [Dore 2019, PMID 30917760; Mathai 2023], repeatedly shows that the same pharmacology under different set and setting produces different experiential and clinical outcomes.

The safety corollary is worth stating plainly: set and setting affect safety as well as therapeutic value. Inadequate set and setting raises the probability of acute panic, prolonged distress, retraumatization, and adverse outcomes with long-tail psychological consequences. This is a clinical reason, not an aesthetic one, to take set and setting seriously.

Key stat: In Carbonaro et al. (2016), 84% of 1,993 respondents endorsed long-term benefit from their most challenging psilocybin experience, even though 11% placed themselves or others at physical risk during the experience. The supervised-setting contrast matters: "the incidence of risky behavior or enduring psychological distress is extremely low when psilocybin is given in laboratory studies to screened, prepared, and supported participants" [Carbonaro 2016, PMID 27578767].

The two-clinician model

One of the most studied structural setting variables is how many clinicians are in the room. The MAPS MDMA-AT manual used in MAPP1 (Mitchell 2021, PMID 33972795) and MAPP2 (Mitchell 2023, PMID 37709999) specifies a co-therapy pair in the dosing room. The COMP001 psilocybin protocol (Goodwin 2022, PMID 36322843) similarly pairs a lead therapist with a co-therapist or sitter. The rationale is well-articulated in the MAPS manual:

• Continuous presence across long sessions without single-clinician fatigue (MDMA and psilocybin dosing sessions run 6–8 hours)
• Two perspectives during clinically ambiguous moments
• Coverage for breaks and any in-session medical needs
• Modelling safe relational dynamics, particularly relevant for trauma work
• Reduced risk of boundary violation as a structural safeguard built into the setting itself

The two-clinician model is more resource-intensive and is one reason MDMA-AT and high-dose psilocybin are clinic-based services. Ketamine-assisted psychotherapy ranges in staffing from a single trained clinician with a sitter to full co-therapy, depending on protocol, substance form, and patient profile.

Music as a key setting variable

Music is not background. In modern psychedelic-assisted therapy protocols, the playlist is part of the medicine. Kaelen et al. (2018, Psychopharmacology, PMID 29396616), working with the Imperial College London group, demonstrated that music chosen for psilocybin sessions made measurable contributions to subjective experience, including emotional response, sense of meaningfulness, and degree of mystical-type experience. The MAPS MDMA-AT manual specifies a curated playlist with a deliberate emotional arc; the COMP001 protocol uses a Compass-developed playlist; ketamine-assisted psychotherapy practices vary.

The clinical question patients face is standardized versus personalized:

Approach	What it offers	Watch out for
Standardized playlists (Imperial / COMPASS style)	Deliberate arcs from opening through peak to landing; team is trained to anticipate emotional contours	Less personal resonance for some patients
Personalized playlists	Music with existing personal meaning	Personal associations can introduce unexpected content during dosing
Semi-standardized with patient exclusions	Most common clinical compromise	Requires preparation conversation to identify what to exclude and why

Most modern protocols default to standardized or semi-standardized playlists, with patient input on whether vocals, language, or specific genres should be excluded. Patient autonomy on music is real but not unlimited; the team's clinical judgment about emotional pacing remains in play. For a deeper look at the research and clinical rationale, see music in psychedelic therapy.

Pro tip: Raise music preferences and any strong negative associations during preparation, not on dosing day. The preparation session is the right time to agree on a playlist framework. Changing the plan on dosing morning adds cognitive load at a moment when reducing pre-session anxiety is the priority.

Eye-mask, inward focus, and non-directive presence

Two further structural setting features are worth naming explicitly.

Eye-mask and inward focus. Most psilocybin and MDMA-AT protocols invite patients to wear an eye-mask for substantial portions of the dosing session, directing attention inward rather than outward. The eye-mask reduces visual stimulation and supports the inner-directed approach. Patients can remove it at any time.

Therapist non-directive presence. The clinician's role during dosing is predominantly non-directive: present, available, calm, and supportive, but not steering content. The MAPS manual is explicit that the therapist follows the patient's process rather than leading it. This is a deliberate setting choice; directive interventions during dosing tend to disrupt the inward arc the medicine and the eye-mask have set up.

These features are not universal. Some ketamine-assisted psychotherapy protocols, particularly at lower doses, are more conversational. The structural choice between inward-directed and dialogic dosing is part of the setting design and should be discussed with the patient in preparation. See what to expect at your first psychedelic-assisted therapy session for more on how the dosing day is structured.

Risks of poor set and setting

When set and setting are inadequate, the documented risk profile shifts:

• Acute panic and overwhelm during dosing, particularly with high-dose psilocybin and MDMA in unfamiliar or unsupportive environments
• Prolonged distress in the days and weeks following dosing [Carbonaro 2016, PMID 27578767]
• Retraumatization when trauma material surfaces and the team or environment cannot hold it safely
• Adverse outcomes with long-tail psychological sequelae that are uncommon in well-prepared, well-set clinical contexts but more common in unstructured or unsupervised use
• Disrupted integration when experiences that occurred in unsafe settings are harder to work with after the fact

These are not theoretical risks. They are why every component of set and setting is treated as clinical work in modern protocols rather than as room design.

How ATMA CENA constructs set and setting

ATMA CENA's clinical environment is designed against the framework above.

Setting: physical and clinical. ATMA CENA's dosing rooms are designed for the inward-directed approach: dim, warm lighting; comfortable recliner-style seating with blankets and pillows; neutral, calming aesthetics; functional but unobtrusive medical monitoring; private bathroom access; and a sound system chosen for fidelity at quiet volumes. Rooms are insulated against interruption, and clinic protocols protect privacy across the session arc.

Setting: social. ATMA CENA's dosing protocols are calibrated by substance and patient profile. Psilocybin- and MDMA-assisted therapy, accessed through Health Canada's case-by-case, physician-initiated approval, follow the two-clinician model in line with COMP001 and MAPP1/MAPP2; ketamine-assisted psychotherapy staffing follows substance, route, dose, and patient-specific clinical judgment. Where clinically possible, the team that accompanies the patient through preparation is the same team present at dosing and through integration.

Setting: cultural and personal. Patients are invited in preparation to identify a meaningful object, a chosen reading, a brief grounding practice, or a similar element if they want one. These elements are patient-led, never imposed, and clinically reviewed.

Set: psychological readiness. The work of stabilizing "set" sits in preparation: alliance-building, education, intention-setting, anchor-skills practice, and contraindication screening.

Set: CoCare. ATMA CENA's CoCare program is particularly relevant to "set." Where a patient already has an established, appropriately trained therapist, ATMA CENA can partner with that therapist through a service agreement. That existing relationship anchors trust and is one of the strongest sources of stable "set" a patient can bring into a dosing session. See ATMA CENA CoCare for the structural detail.

What patients can do to optimize their own set

The setting is engineered by the clinic. The set is a collaboration. Patients have meaningful input on the components of set that are theirs.

• Sleep. Aim for two consecutive nights of adequate sleep before the dosing session. Sleep deprivation degrades baseline state.
• Hydration and food. Follow your clinic's instructions on the day of dosing. Most psilocybin and MDMA protocols include a light meal a few hours before.
• Reduce stimulant load. Caffeine at your normal level on the morning of dosing is usually fine; ramped-up caffeine, nicotine, or stimulants beyond your baseline are not.
• Substance use. Alcohol the night before is generally discouraged. Recreational substance use in the 48 hours before dosing is a clinical concern; raise it honestly with your team.
• Conflict and acute stress. Where possible, avoid high-conflict conversations or peak-stress events in the 48 hours before dosing.
• Re-read your intentions. The day before dosing, re-read the intentions you set in preparation. They are reference points, not goals.
• Communicate any change in your state. Sleep, mood, recent events, new medications, illness: tell your team before the session, not after. A small communication before dosing is far better than an unaddressed factor during it.
• Bring what you've been told you can bring. A meaningful object, a chosen item of clothing, a short reading. Within the clinic's protocol.
• Trust the protocol you co-built in preparation. The preparation work is the dosing-day foundation. Trust it.

These levers are not large in isolation; together they represent how a patient enters the session with the strongest set they can assemble.

What set and setting does not do

• Set and setting is necessary, not sufficient. Substance, dose, screening, and integration all matter independently. Excellent set and setting does not rescue an inappropriate substance choice or inadequate screening.
• Strong set and setting does not guarantee a strong outcome. Goodwin 2022 COMP001 showed 37% response and 29% remission at the 25 mg psilocybin dose at week 3 in treatment-resistant depression (n=79 at that dose arm) inside a tightly engineered set-and-setting envelope [Goodwin 2022, PMID 36322843].
• Set and setting cannot make a patient eligible. Contraindications are clinical (personal or family history of psychotic disorder, uncontrolled cardiovascular disease, pregnancy, certain medication interactions) and are not modulated by environment.
• Set and setting cannot substitute for the substance. The pharmacology supplies the non-ordinary state; the set and setting shape what that state becomes. Removing the substance does not leave a therapy that works the same way.

---

Frequently asked questions

Where does the phrase "set and setting" come from?

The framework is generally credited to Timothy Leary, George Litwin and Ralph Metzner's 1963 paper Reactions to psilocybin administered in a supportive environment (PMID 14087676), and was re-examined for modern clinical practice by Ido Hartogsohn's 2017 work, particularly Set and Setting, Psychedelics and the Placebo Response in the Journal of Psychopharmacology (PMID 28443452). Hartogsohn's contribution was to argue that set and setting are not ancillary to the drug effect but constitutive of it: the pharmacology supplies the non-ordinary state, and the set and setting shape what that state becomes for the patient.

What is the difference between set and setting?

Set is internal: the patient's mindset, expectations, intentions, personality, and history coming into the session, plus acute state on dosing day (sleep, hydration, mood, events of the prior 48 hours). Setting is external: the physical, social, clinical, and cultural environment in which the experience takes place. Both matter. Set is built partly in preparation; setting is engineered by the clinic with patient input on the variables that personalize meaningfully.

Why are there usually two clinicians in the dosing room?

The two-clinician (co-therapy) model is built into the MAPS MDMA-AT manuals used in Mitchell 2021 MAPP1 (PMID 33972795) and Mitchell 2023 MAPP2 (PMID 37709999), and the COMP001 psilocybin protocol (Goodwin 2022, PMID 36322843). The rationale is continuous presence across sessions that run 6–8 hours, two-perspective clinical judgment during ambiguous moments, coverage for breaks, modelling safe relational dynamics, and a structural safeguard against boundary violation. Ketamine-assisted psychotherapy staffing varies by substance, dose, and patient.

Why is music a clinical variable and not just atmosphere?

Because Kaelen et al. (2018, Psychopharmacology, PMID 29396616) showed that music chosen for psilocybin sessions made measurable contributions to subjective experience, including emotional response, sense of meaningfulness, and degree of mystical-type experience. The MAPS, COMPASS, and Imperial protocols treat curated audio as part of the therapy, not background. Most modern protocols use standardized or semi-standardized playlists with patient input on exclusions. For the full research picture, see music in psychedelic therapy.

Can I bring my own music?

Sometimes, with clinical review. Most modern protocols default to standardized playlists because their emotional arcs are predictable for the clinical team. Personalized music can introduce associations a patient did not anticipate during dosing. The decision is made in preparation; raise any strong preferences or concerns during those sessions.

Why an eye-mask?

The eye-mask supports the inward-directed approach used in psilocybin and MDMA-AT protocols. It reduces visual stimulation and helps direct attention inward rather than outward. Patients can remove it at any time; the team will not insist on it if the patient is distressed.

Is the therapist supposed to talk to me during the session?

In most psilocybin and MDMA-AT protocols, the dominant clinical posture is non-directive: present, available, calm, and supportive, but not steering content. The therapist follows the patient's process rather than leading it. Ketamine-assisted psychotherapy protocols vary; lower-dose ketamine sessions can be more conversational. This is discussed in preparation so there are no surprises on dosing day.

What if I do not like the room or the music?

Raise it in preparation. Setting choices are clinical, but patient input on the variables that personalize meaningfully is built into the model. Music exclusions, lighting preferences, the temperature of the room, a specific blanket, a meaningful object: these conversations belong in the preparation phase, not on dosing day.

Does set and setting matter as much for ketamine as for psilocybin or MDMA?

The literature increasingly says yes, with calibration. Dore et al. (2019, PMID 30917760) and Mathai et al. (2023) document substantive differences in clinical outcomes between ketamine delivered as an infusion only and ketamine delivered with a psychotherapy frame and intentional set and setting. The effect is most studied at higher doses and longer-duration substances, but the principle generalizes.

Can my existing therapist contribute to my set?

Yes. This is a core argument for ATMA CENA's CoCare program. An existing therapeutic alliance is one of the strongest sources of stable set a patient can bring into a dosing session. Through CoCare, ATMA CENA can partner with your existing therapist, if they have the appropriate training, through a service agreement, while ATMA CENA's clinical infrastructure provides the medical supervision and the medication-specific frame.

If set and setting are so important, can a perfect environment make the medicine work?

No. Set and setting is necessary, not sufficient. Substance, dose, screening, preparation, and integration all matter independently. Excellent set and setting supports safety and quality of the experience; it does not predict clinical response and does not replace the clinical work surrounding it.

---

Compliance disclaimer

This article is educational. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act (Schedule III and Schedule I respectively). Legal patient access to psilocybin- or MDMA-assisted therapy in Canada requires Health Canada approval on a case-by-case basis, initiated by a physician, and is not guaranteed. Where access is granted, it is generally limited to defined clinical circumstances, such as adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness for psilocybin, and adults with PTSD for MDMA. Ketamine is approved by Health Canada as an anaesthetic; use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators (e.g., CPSA in Alberta, CPSO in Ontario, CPSM in Manitoba). Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression in adults aged 18–64. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

View Reverdi Darda, RN, BScN's profile and other articles

Sources

1. Leary T, Litwin GH, Metzner R. (1963). Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease, 137:561-573. PMID: 14087676. https://pubmed.ncbi.nlm.nih.gov/14087676/
2. Hartogsohn I. (2017). Set and Setting, Psychedelics and the Placebo Response: An Extra-Pharmacological Perspective on Psychopharmacology. Journal of Psychopharmacology, 31(8):1259-1267. PMID: 28443452. https://pubmed.ncbi.nlm.nih.gov/28443452/
3. Hartogsohn I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3:1-17. https://doi.org/10.1177/2050324517723279
4. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795. https://www.nature.com/articles/s41591-021-01336-3
5. Mitchell JM, Ot'alora GM, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999. https://www.nature.com/articles/s41591-023-02565-4
6. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843. https://www.nejm.org/doi/full/10.1056/NEJMoa2206443
7. Kaelen M, Giribaldi B, Raine J, et al. (2018). The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology, 235(2):505-519. PMID: 29396616. https://pubmed.ncbi.nlm.nih.gov/29396616/
8. Carbonaro TM, Bradstreet MP, Barrett FS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12):1268-1278. PMID: 27578767. https://pubmed.ncbi.nlm.nih.gov/27578767/
9. Preller KH, Vollenweider FX. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences, 36:221-256. PMID: 28025814. https://pubmed.ncbi.nlm.nih.gov/28025814/
10. Dore J, Turnipseed B, Dwyer S, et al. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs, 51(2):189-198. PMID: 30917760. https://pubmed.ncbi.nlm.nih.gov/30917760/
11. Mathai DS, Mora V, Garcia-Romeu A. (2023). Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology, 13:868103. https://www.frontiersin.org/articles/10.3389/fpsyg.2022.868103/full
12. Health Canada: Requests to the case-by-case access pathway for psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles

• The Psychedelic-Assisted Therapy Pathway in Canada: parent pathway hub
• The Preparation Phase of Psychedelic-Assisted Therapy: building set before dosing day
• Music in Psychedelic-Assisted Therapy: the evidence and clinical rationale for the playlist
• What to Expect at Your First Psychedelic-Assisted Therapy Session: the full assessment and dosing-day walkthrough

---

Last updated: 2026-05-28. Article is reviewed every 12 months or when material regulatory or clinical-trial developments occur.